Leveraged Solana and XRP ETFs gain $3B momentum ahead of SEC decision

Exchange-traded funds linked to Solana and XRP have seen a surge in trading volume, reaching nearly $3 billion as the market awaits potential spot ETF approvals.

This increase in activity can be attributed to the introduction of new leveraged products, a rise in derivatives trading, and the demand for yield-focused investment structures.

Futures Solana ETF (Source: The Block)
Futures Solana ETFs (Source: The Block)

In early 2025, news of the CME Group preparing to list futures contracts for Solana and XRP led to a 3% price increase. This development paved the way for institutional product launches based on regulated derivatives markets.

By mid-May, open interest in XRP futures surged by $1 billion within a week, with prices moving from $2.10 to $2.45. This uptick in activity coincided with speculation of a potential spot XRP ETF approval by the U.S. Securities and Exchange Commission.

ProShares introduced leveraged futures ETFs for Solana and XRP in July following NYSE Arca approval. These ETFs aim to deliver double the daily performance of their respective CME-regulated futures without holding the underlying assets.

Additionally, the REX-Osprey Solana Staking ETF, launched in early July, garnered significant trading volume and inflows. This spot-based ETF integrates staking rewards, offering investors a yield-bearing exposure in the digital asset market.

Data from ETFs in July showed inflows of $20 million for Solana-linked ETFs and $10 million for XRP ETFs, contributing to a total of $189 billion in crypto ETF assets under management.

While futures-based ETFs differ from spot products in structure and exposure, their growth and trading activity showcase the market’s depth and liquidity in altcoins.

The convergence of increased futures trading, substantial ETF inflows, and innovative yield-focused structures has elevated Solana and XRP in regulated investment markets.

The $3 billion mark in futures-based ETF assets indicates significant capital allocation in anticipation of regulatory changes.

Mentioned in this article